Literature DB >> 1017885

Dextran-induced anaphylactoid reactions in man: role of dextran reactive antibodies.

H Hedin, W Richter, J Ring.   

Abstract

Dextran reactive antibodies (DRA) were studied in 123 patients having experienced dextran-induced anaphylactoid reactions (DIAR) during 1970-1975. No evidence for reaginic DRA was obtained by radioallergosorbent technique and passive cutaneous anaphylaxis in Cynomolgus monkeys; total IgE levels were within normal range. It is concluded that DIAR are not mediated by dextran-specific reagins. Further, no reaginic antibodies against potential contaminants from the dextran manufacturing process were demonstrable. In two population samples of normal human sera from Sweden and Germany hemagglutinating DRA (IgG, IgA, and IgM classes) were found in 63 and 74%, high titres (16-256) comprising 14 and 25%. In dextran reactors a direct positive correlation between titres of hemagglutinating DRA and increasing severity of DIAR was observed. The accumulation of high DRA titres in severe reactions may be taken as circumstantial evidence for the causal role of hemagglutinating DRA in these cases. However, if high titres of DRA alone were responsible for triggering DIAR, the expected frequency would be more than thousand times higher than the reported global incidence of DIAR. To explain this discrepancy, involvement of certain Ig classes or subgroups, possibly in combination with other predisposing factors is suggested. In mild reactions DRA appear to play a negligible role. Positive dextran wheal and flare reactions, often correlated with high titres of hemagglutinating DRA, were seen in 32% of dextran reactors, indicating that skin tests are of limited predictive value. No significant difference between sexes, age groups, or pre- and intraoperatively started dextran infusions was observed; association with certain diseases was not apparent.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1017885     DOI: 10.1159/000231676

Source DB:  PubMed          Journal:  Int Arch Allergy Appl Immunol        ISSN: 0020-5915


  11 in total

Review 1.  Anaphylaxis and anaphylactoid reactions. Classification and pathophysiology.

Authors:  J Ring; H Behrendt
Journal:  Clin Rev Allergy Immunol       Date:  1999       Impact factor: 8.667

Review 2.  Anaphylactoid reactions to intravenous solutions used for volume substitution.

Authors:  J Ring
Journal:  Clin Rev Allergy       Date:  1991 Fall-Winter

Review 3.  Adverse reactions to plasma volume expanders.

Authors:  M M Fisher; P W Brady
Journal:  Drug Saf       Date:  1990 Mar-Apr       Impact factor: 5.606

4.  A randomised prospective study of treatment of non-ischaemic central retinal vein occlusion by isovolaemic haemodilution.

Authors:  L L Hansen; J Wiek; M Wiederholt
Journal:  Br J Ophthalmol       Date:  1989-11       Impact factor: 4.638

Review 5.  Anaphylaxis.

Authors:  A I Terr
Journal:  Clin Rev Allergy       Date:  1985-02

6.  Incidence and classification of adverse reactions to plasma substitutes.

Authors:  J Ring; H Laubenthal; K Messmer
Journal:  Klin Wochenschr       Date:  1982-09-01

Review 7.  Idiopathic anaphylaxis.

Authors:  Johannes Ring; Ulf Darsow
Journal:  Curr Allergy Asthma Rep       Date:  2002-01       Impact factor: 4.806

Review 8.  Basophils in human disease.

Authors:  E B Mitchell; P W Askenase
Journal:  Clin Rev Allergy       Date:  1983-09

9.  Incidences of fatal postoperative pulmonary embolism after prophylaxis with dextran 70 and low-dose heparin: an international multicentre study.

Authors:  U F Gruber; T Saldeen; T Brokop; B Eklöf; I Eriksson; I Goldie; L Gran; M Hohl; T Jonsson; S Kristersson; K G Ljungström; T Lund; H M Moe; E Svensjö; D Thomson; J Torhorst; A Trippestad; M Ulstein
Journal:  Br Med J       Date:  1980-01-12

10.  Lack of evidence for IgM-induced ADCC: studies with monoclonal and polyclonal antibodies.

Authors:  H Rumpold; G Wiedermann; O Scheiner; D Kraft; H Stemberger
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.